Sponsored by:
Cell Line Characterization: Ensuring the identity, purity, and safety of your cell banks and resulting biologic products
We draw on over 75 years of trusted expertise in biosafety testing to support the safety and quality of your biopharmaceutical programs.
Our global teams have delivered thousands of Cell Line Characterization (CLC) studies across a broad range of cell lines, helping ensure the highest standards of quality, reliability, and regulatory confidence.
Building on our established facilities in the US and UK, and decades of proven experience in Cell Line Characterization, we are now bringing our CLC services to our Singapore site, with operations set to begin in November 2026. This expansion marks a major milestone in our footprint and capabilities across the Asia-Pacific region.
Reach out to our team of experts today to learn how to secure your pre-opening slot and enjoy a competitive Early Bird advantage for your coming cell line characterization project.
Our State-of-the-art Cell Line Characterization Package includes:
- NGS for Adventitious Agent Testing: Reduce animal use by replacing in vivo testing with faster turnaround time, less sample requirements, better risk mitigation, and alignment with regulatory guidelines’ recommendation.
- Blazar® tNGS Rodent Virus Panel: Detect and identify viral contaminants with high sensitivity while offering significantly faster turnaround times than traditional in vivo (MAP/HAP/RAP) testing.
- Aptegra® platform: Leverage on the power of whole genome sequencing by NGS to obtain more comprehensive information supporting the integrity of integrated transgenes to replace the conventional panel of genetic stability assays (Sanger sequencing of transgenes and flanking regions, Southern blot, ddPCR, and FISH) with less sample requirements (2e6 vs 2e8), faster turnaround time (30 days vs 3-5 months), and all at a lower cost.
